Article Text

Download PDFPDF
Fatal invasive pulmonary aspergillosis associated with adalimumab therapy
  1. M Manz1,
  2. C Beglinger1,
  3. S R Vavricka1,2
  1. 1
    Division of Gastroenterology, University Hospital Basel, Switzerland
  2. 2
    Division of Gastroenterology, University Hospital Zurich, Switzerland
  1. Dr S R Vavricka, Division of Gastroenterology and Hepatology, University Hospital, Raemistrasse 100, CH-8091 Zurich, Switzerland; stephan.vavricka{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the article by Sandborn et al (Gut 2007;56:1232–9) about maintenance therapy of Crohn’s disease with adalimumab and the recent publication by Viget et al (Gut 2008;57:549–58) on opportunistic infections in patients with inflammatory bowel disease. In their series including 276 patients, Sandborn et al note no severe infectious complications apart from upper respiratory tract infections. It is noteworthy that no cases of aspergillosis or other opportunistic infections were reported.

Unfortunately, serious infections are a well known problem of tumour necrosis factor α (TNFα) antibody therapies. Here, we present a case report of a 69-year-old female patient with a long history of stenosing Crohn’s disease. The patient …

View Full Text


  • Funding: This work is supported by Grant 320000-114009/1 (to SRV), and 3347C0-108792/1 (Swiss IBD Cohort Study) from the Swiss National Science Foundation.

  • Competing interests: None.

  • Patient consent: Obtained from the patient’s family.